Dr Lal Pathlabs | BUY

Improving growth and attractive valuations; Upgrade to BUY

Dr.Lal's (DLPL) stock price has declined ~20% from its recent highs. Our downgrade after 1Q results was primarily due to weak visibility on volumes and expensive valuations. Post the recent correction, however DLPL trades near -1 SD along with sample volume growth returning to double digits during the quarter. Overall, DLPL's results were largely in-line with our estimates. The company reported 11% revenue growth, alongside 10%/19% growth in EBITDA/PAT, with margins contracting 30bps YoY, due to higher growth in staff cost. The 11% YoY revenue growth was driven completely by sample volume growth. As the company plans to add 15-20 labs, we anticipate growth could accelerate starting FY26. We project 12-13% top-line growth in FY26/27, with margins expected to remain above 27%, aided by an improving Swasthfit mix (currently at 24%). Attractive valuations, steady growth and margins warrant an upgrade to BUY. We largely maintain our earnings estimates as well as target multiple and roll forward to Dec'26 TP of INR 3,600 (25% upside).

- Double digit test volume growth: Test volume grew ~11% to 20.6mn and patient volume grew 3%YoY to 6.9mn. The company achieved this through deeper penetration in core markets as well as concerted efforts to grow in the West and South region. The high-margin 'Swasthfit' portfolio contributed ~23% to revenue (vs. 20% in 3QFY24) for the quarter (24% for 9MFY25) and is expected to further improve. Realisation per patient increased 7.5% YoY at INR 865 driven by mix and not price. Future growth in this metric will maintain this trend going forward. At an industry level test pricing is stabilising with predatory pricing/deep-discounting now receding
- Gross margins to stabilise at 80%: The management guided for gross margins to stabilise going ahead as the company will face some headwinds in terms of rising reagent costs due to rupee depreciation. However, increasing sample and patient volume are driving operating leverage; this enables the company to maintain competitive pricing and their EBITDA margins. The management are averse to pricing led growth, and will not take any price increases over the next 6-9 months. We have built in 10.7%YoY for FY25 and 12-13% for FY26/27 which will be driven by volume ramp-up, higher Swasthfit contribution and network expansion. DLPL plans to roll out Swasthfit to Tier 3/4 cities and also widen its scope.
- Network expansion on track: The company is on track to open 15-20 labs this year. DLPL is expanding their reach into Tier 3 and Tier 4 markets while strengthening presence in the core regions. They are making investments in new infrastructure in Metro / Tier 1 cities as well. The majority of capex outlay is back-ended. Some of the expansion initiatives are visible in higher employee costs as the company builds out its front end presence. The company indicated that so far they have spent INR 300mn in lab expansion efforts.
- West the fastest growing: West region was a key driver for the company and was the fastest growing region for the quarter and YTD. During the quarter/9M suburban grew 9.2%/9.8% YoY with margins for trending at 15-16% for the year so far, with 3Q

Financial Summary					(INR mn)
Y/E March	FY23A	FY24A	FY25E	FY26E	FY27E
Net Sales	20,169	22,266	24,645	27,669	31,197
Sales Growth (%)	-3.4	10.4	10.7	12.3	12.8
EBITDA	4,899	6,093	6,860	7,657	8,553
EBITDA Margin (%)	24.3	27.4	27.8	27.7	27.4
Adjusted Net Profit	2,389	3,577	4,346	4,954	5,629
Diluted EPS (INR)	28.6	42.9	52.1	59.4	67.5
Diluted EPS Growth (%)	-30.7	49.7	21.5	14.0	13.6
ROIC (%)	20.5	31.1	38.7	47.7	61.0
ROE (%)	15.1	20.3	22.4	23.3	24.3
P/E (x)	100.5	67.1	55.2	48.4	42.6
P/B (x)	14.4	13.0	11.8	10.8	10.0
EV/EBITDA (x)	47.6	37.9	33.3	29.5	26.0
Dividend Yield (%)	0.5	0.8	0.9	1.1	1.3

Source: Company data, JM Financial. Note: Valuations as of 30/Jan/2025



Amey Chalke amey.chalke@jmfl.com | Tel: (91 22) 66303056

Recommendation and Price Target							
Current Reco.	BUY						
Previous Reco.	HOLD						
Current Price Target (12M)	3,600						
Upside/(Downside)	25.1%						
Previous Price Target	3,465						
Change	3.9%						
Key Data – DLPL IN							
Current Market Price	INR2,878						
Market cap (bn)	INR240.6/US\$2.8						
Free Float	42%						
Shares in issue (mn)	83.3						
Diluted share (mn)	83.4						
3-mon avg daily val (mn)	INR594.3/US\$6.9						
52-week range	3,654/1,943						
Sensex/Nifty	76,760/23,250						

Price Performan	ce		
%	1M	6M	12M
Absolute	-2.6	-6.9	16.2
Relative*	-0.7	-1.2	7.7

86.6

* To the BSE Sensex

INR/US\$

JM Financial Research is also available on: Bloomberg - JMFR <GO>, Thomson Publisher & Reuters, S&P Capital IQ, FactSet and Visible Alpha

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification. witnessing a dip in margins as it is a seasonally weak quarter. DLPL's boad has given an in-principle approval for expeditious consolidation of Suburban's business. This should lead to some savings in administrative and legal costs.


- Key financials:
 - Revenue/EBITDA/PAT for the quarter were INR 6bn/1.5bn/967mn grew 11%/10%/19% YoY and were in line vs JMFe and in-line/-3%/-3% vs. consensus estimates;
 - Gross Margins come in at 80.4% (vs JMFe 80%, 80.1% YoY); Going ahead management expect Gross margins to stabilise at these levels
 - EBITDA margins were 25.8% (vs. JMFe 26%, 26.1% YoY), and contracted due to higher employee expense;



Source: Bloomberg, JM Financial

Exhibit 2. Tier 3+ has been ramping up well						
Tier 3+	FY20	FY21	FY22	FY23	FY24	
Revenue Tier 3	421	544	683	685	789	
Total Revenues	1330	1581	2087	2017	2227	
% of Total	31.7%	34.4%	32.7%	34.0%	35.4%	
Revenue growth		29.2%	25.6%	0.3%	15.2%	
Infra in Tier 3						
Labs	60	64	69	70	84	
СС	1762	1988	2416	2848	3446	
PUPs	4475	5560	6363	6863	7668	
CC per lab	29	31	35	41	41	
PUP per lab	75	87	92	98	91	

Source: Company



Source: Company, JM Financial

Dr. Lal - P&L (INR mn)	3Q24A	3Q25A	% YoY	3Q25E	% Delta vs. JMFe	3Q25E (cons)	% Delta vs. cons	2Q25A	% QoQ
Total Revenue	5,389	5,967	11%	5,991	0%	5,997	-1%	6,602	-10%
COGS	1,070	1,170	9%	1,198	-2%			1,273	-8%
Gross Profit	4,319	4,797	11%	4,793	0%			5,329	-10%
Gross Profit %	80.1%	80.4%	25 bps	80.0%	39 bps			80.7%	-33 bps
Staff Cost	1,090	1,264	16%	1,258	0%			1,240	2%
Other expenses	1,823	1,993	9%	1,977	1%			2,064	-3%
EBITDA	1,406	1,540	10%	1,558	-1%	1,591	-3%	2,025	-24%
EBITDA margin (%)	26.1%	25.8%	-28 bps	26.0%	-19 bps	26.5%	-72 bps	30.7%	-486 bps
Other Income	183	251	37%	225	12%			219	15%
Finance Cost	70	53		65				60	
Depreciation	360	355		360				353	
РВТ	1,159	1,383	19%	1,358	2%			1,831	-24%
Exceptional Items	0	0		0				0	
Тах	337	402		380				523	
Tax Rate (%)	29.1%	29.1%		28.0%				28.6%	
Minority Interest	9	14		12				16	
PAT (Reported)	813	967	19%	966	0%	995	-3%	1,292	-25%
PAT margin (%)	15.1%	16.2%		16.1%		16.6%		19.6%	
Diluted EPS (INR)	9.8	11.6	19%	11.6	0%			15.5	-25%

Dr. Lal - Cost margins	3Q24A	3Q25A	% YoY	3Q25E	% Delta vs. JMFe	2Q25A	% QoQ
COGS/sales	19.9%	19.6%	-25 bps	20.0%	-39 bps	19.3%	33 bps
Staff cost/sales	20.2%	21.2%	96 bps	21.0%	18 bps	18.8%	240 bps
Other expenditure/sales	33.8%	33.4%	-43 bps	33.0%	40 bps	31.3%	214 bps

Source: Company, JM Financial, Bloomberg

Financial Tables (Consolidated)

Income Statement				(NR mn)
Y/E March	FY23A	FY24A	FY25E	FY26E	FY27E
Net Sales	20,169	22,266	24,645	27,669	31,197
Sales Growth	-3.4%	10.4%	10.7%	12.3%	12.8%
Other Operating Income	0	0	0	0	0
Total Revenue	20,169	22,266	24,645	27,669	31,197
Cost of Goods Sold/Op. Exp	4,472	4,514	4,830	5,534	6,395
Personnel Cost	3,765	4,245	4,945	5,486	6,172
Other Expenses	7,033	7,414	8,010	8,993	10,077
EBITDA	4,899	6,093	6,860	7,657	8,553
EBITDA Margin	24.3%	27.4%	27.8%	27.7%	27.4%
EBITDA Growth	-12.6%	24.4%	12.6%	11.6%	11.7%
Depn. & Amort.	1,502	1,436	1,417	1,549	1,653
EBIT	3,397	4,657	5,443	6,107	6,900
Other Income	417	692	934	1,062	1,208
Finance Cost	375	294	220	300	315
PBT before Excep. & Forex	3,439	5,055	6,157	6,869	7,793
Excep. & Forex Inc./Loss(-)	0	0	0	0	0
PBT	3,439	5,055	6,157	6,869	7,793
Taxes	1,028	1,432	1,755	1,855	2,104
Extraordinary Inc./Loss(-)	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	22	46	56	60	60
Reported Net Profit	2,389	3,577	4,346	4,954	5,629
Adjusted Net Profit	2,389	3,577	4,346	4,954	5,629
Net Margin	11.8%	16.1%	17.6%	17.9%	18.0%
Diluted Share Cap. (mn)	83.4	83.4	83.4	83.4	83.4
Diluted EPS (INR)	28.6	42.9	52.1	59.4	67.5
Diluted EPS Growth	-30.7%	49.7%	21.5%	14.0%	13.6%
Total Dividend + Tax	1,030	2,012	2,549	3,059	3,690
Dividend Per Share (INR)	15.6	24.0	26.0	31.2	37.6

Balance Sheet					(INR mn)
Y/E March	FY23A	FY24A	FY25E	FY26E	FY27E
Shareholders' Fund	16,663	18,493	20,289	22,184	24,123
Share Capital	834	835	834	834	834
Reserves & Surplus	15,829	17,658	19,455	21,350	23,289
Preference Share Capital	0	0	0	0	C
Minority Interest	332	361	417	477	537
Total Loans	2,366	833	833	833	833
Def. Tax Liab. / Assets (-)	-375	-425	-425	-425	-425
Total - Equity & Liab.	18,986	19,262	21,114	23,069	25,068
Net Fixed Assets	13,100	11,995	11,728	10,880	9,998
Gross Fixed Assets	10,338	11,194	12,344	13,045	13,817
Intangible Assets	9,060	8,525	8,525	8,525	8,525
Less: Depn. & Amort.	6,328	7,764	9,181	10,730	12,384
Capital WIP	30	40	40	40	40
Investments	1,499	1,138	1,138	1,138	1,138
Current Assets	8,852	10,978	13,385	16,653	20,080
Inventories	338	373	413	464	523
Sundry Debtors	708	774	857	962	1,084
Cash & Bank Balances	6,654	8,303	10,515	13,534	16,672
Loans & Advances	14	13	14	16	18
Other Current Assets	1,138	1,515	1,586	1,677	1,782
Current Liab. & Prov.	4,465	4,849	5,137	5,601	6,148
Current Liabilities	2,861	2,896	3,027	3,318	3,674
Provisions & Others	1,604	1,953	2,110	2,284	2,474
Net Current Assets	4,387	6,129	8,248	11,051	13,932
Total – Assets	18,986	19,262	21,114	23,069	25,068

Source: Company, JM Financial

Source: Company, JM Financial

Cash Flow Statement				((INR mn)
Y/E March	FY23A	FY24A	FY25E	FY26E	FY27E
Profit before Tax	3,439	5,055	6,157	6,869	7,793
Depn. & Amort.	1,502	1,436	1,417	1,549	1,653
Net Interest Exp. / Inc. (-)	43	-260	-640	-687	-819
Inc (-) / Dec in WCap.	355	357	93	216	257
Others	286	86	10	10	10
Taxes Paid	-1,065	-1,320	-1,755	-1,855	-2,104
Operating Cash Flow	4,560	5,354	5,282	6,102	6,790
Capex	-446	-575	-1,150	-702	-772
Free Cash Flow	4,114	4,779	4,132	5,401	6,019
Inc (-) / Dec in Investments	-2,733	-141	0	0	0
Others	306	473	850	978	1,124
Investing Cash Flow	-2,873	-243	-300	276	352
Inc / Dec (-) in Capital	8	35	-1	0	0
Dividend + Tax thereon	-1,030	-2,012	-2,549	-3,059	-3,690
Inc / Dec (-) in Loans	-1,432	-1,868	0	0	0
Others	-378	-294	-220	-300	-315
Financing Cash Flow	-2,832	-4,139	-2,770	-3,359	-4,005
Inc / Dec (-) in Cash	-1,145	972	2,212	3,019	3,138
Opening Cash Balance	3,782	2,637	3,609	5,821	8,840
Closing Cash Balance	6,654	8,303	10,515	13,534	16,672

Dupont Analysis Y/E March FY23A FY24A FY25E FY26E FY27E Net Margin 11.8% 16.1% 17.6% 17.9% 18.0% Asset Turnover (x) 1.1 1.1 1.2 1.2 1.0 Leverage Factor (x) 1.3 1.2 1.1 1.1 1.1 RoE 15.1% 20.3% 22.4% 23.3% 24.3%


Key Ratios					
Y/E March	FY23A	FY24A	FY25E	FY26E	FY27E
BV/Share (INR)	199.8	221.7	243.3	266.0	289.2
ROIC	20.5%	31.1%	38.7%	47.7%	61.0%
ROE	15.1%	20.3%	22.4%	23.3%	24.3%
Net Debt/Equity (x)	-0.3	-0.5	-0.5	-0.6	-0.7
P/E (x)	100.5	67.1	55.2	48.4	42.6
P/B (x)	14.4	13.0	11.8	10.8	10.0
EV/EBITDA (x)	47.6	37.9	33.3	29.5	26.0
EV/Sales (x)	11.6	10.4	9.3	8.2	7.1
Debtor days	13	13	13	13	13
Inventory days	6	6	6	6	6
Creditor days	37	42	41	42	43

Source: Company, JM Financial

Source: Company, JM Financial

Dr Lal Pathlabs

History of Recomm	nendation and Ta	arget Price	
Date	Recommendation	Target Price	% Chg.
4-Jul-22	Buy	2,570	
28-Jul-22	Buy	2,570	0.0
9-Nov-22	Buy	2,900	12.8
2-Feb-23	Buy	2,735	-5.7
20-Mar-23	Buy	2,620	-4.2
11-May-23	Buy	2,525	-3.6
4-Jul-23	Buy	2,525	0.0
27-Jul-23	Buy	2,610	3.4
2-Nov-23	Buy	2,575	-1.3
1-Feb-24	Buy	2,665	3.5
10-May-24	Buy	2,735	2.6
8-Aug-24	Hold	3,425	25.2
23-Oct-24	Hold	3,465	1.2



JM Financial Institutional Securities Limited

APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: sahil.salastekar@jmfl.com

Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Definition of	Definition of ratings					
Rating	Meaning					
Buy Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.						
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.					
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.					

* REITs refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., <u>JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 28th Floor, Office No. 2821, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.</u>

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.